July 2018
Volume 59, Issue 9
Open Access
ARVO Annual Meeting Abstract  |   July 2018
Nucleoside reverse transcriptase inhibitors are broad-spectrum RPE protectants
Author Affiliations & Notes
  • Shuichiro Hirahara
    Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Shinichi Fukuda
    Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Younghee Kim
    Ophthalmology, University of Kentucky, Lexington, Kentucky, United States
  • Reo Yasuma
    Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Kameshwari Ambati
    Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Junichi Fukuhara
    Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Dongxu Fu
    Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • DAIPAYAN BANERJEE
    Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Benjamin J Fowler
    Ophthalmology, University of Kentucky, Lexington, Kentucky, United States
  • Tetsuhiro Yasuma
    Ophthalmology, University of Kentucky, Lexington, Kentucky, United States
  • Nagaraj Kerur
    Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Bradley Gelfand
    Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Jayakrishna Ambati
    Ophthalmology, University of Virginia, Charlottesville, Virginia, United States
  • Footnotes
    Commercial Relationships   Shuichiro Hirahara, None; Shinichi Fukuda, None; Younghee Kim, None; Reo Yasuma, None; Kameshwari Ambati, None; Junichi Fukuhara, None; Dongxu Fu, None; DAIPAYAN BANERJEE, None; Benjamin Fowler, University of Kentucky (P); Tetsuhiro Yasuma, None; Nagaraj Kerur, University of Virginia (P); Bradley Gelfand, None; Jayakrishna Ambati, Allergan (C), Allergan (R), Inflammasome Therapeutics (I), iVeena (I), Olix Pharmaceuticals (C), Olix Pharmaceuticals (R), University of Kentucky (P), University of Virginia (P)
  • Footnotes
    Support  NIH/NIGMS, NIH/NEI, John Templeton Foundation, Dupont Guerry, III Professorship
Investigative Ophthalmology & Visual Science July 2018, Vol.59, 2459. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shuichiro Hirahara, Shinichi Fukuda, Younghee Kim, Reo Yasuma, Kameshwari Ambati, Junichi Fukuhara, Dongxu Fu, DAIPAYAN BANERJEE, Benjamin J Fowler, Tetsuhiro Yasuma, Nagaraj Kerur, Bradley Gelfand, Jayakrishna Ambati; Nucleoside reverse transcriptase inhibitors are broad-spectrum RPE protectants. Invest. Ophthalmol. Vis. Sci. 2018;59(9):2459.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Age-related macular degeneration (AMD) is the leading cause of legal blindness among people aged over 60 years especially in developed countries. AMD is a multifaceted disease with numerous potential environmental and molecular instigators contributing to retinal pigmented epithelial (RPE) death. We recently demonstrated nucleoside reverse transcriptase inhibitors (NRTIs), a widely used class of drugs to treat Human Immunodeficiency Virus-1 (HIV), possess anti-inflammatory activity by preventing NLRP3 inflammasome activation. The purpose of this study is to test whether NRTIs possesses the anti-inflammatory ability against these multiple toxic substances regarded as contributors to dry AMD.

Methods : To model RPE degeneration in dry AMD, wild-type mice were subjected to subretinal injection of Amyloid β (Aβ)1-40, poly(I:C) (pIC), iron (Fe (III)), cigarette smoke extract (CSE), paraquat, sodium iodate (NaIO3) or Leu Leu OMe to induce lysosomal destabilization. NRTIs (lamivudine (3TC), stavudine (d4T), azidothymidine (AZT)) or NRTIs modified by alkylation which eliminates reverse transcriptase activity, were administered intraperitoneally or by intravitreous injection in wild-type male C57BL6/J mice. RPE degeneration was assessed by fundus photography and Zonula occludens-1 (ZO-1) staining of RPE flat mounts.

Results : Twice daily intraperitoneal administration of the NRTIs, at a dose equivalent to what is administered in humans, inhibited RPE degeneration in the mouse models of dry AMD caused by Aβ1-40, pIC, Fe (III) or paraquat. Further, one-time intravitreous injection of the NRTIs or modified NRTIs prevented the RPE degeneration induced by Aβ, pIC, Fe (III), CSE, paraquat, NaIO3, Leu Leu OMe or Alu RNA.

Conclusions : The novel anti-inflammatory activity of NRTIs and modified NRTIs prevented RPE toxicity in eight models of dry AMD. Therefore NRTIs and modified NRTIs compounds may be well-suited for therapeutic protection of RPE in dry AMD.

This is an abstract that was submitted for the 2018 ARVO Annual Meeting, held in Honolulu, Hawaii, April 29 - May 3, 2018.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×